



Patent Docket P1762R1

Base -seq

1627

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of  
Andrea G. Cochran et al.  
Serial No.: 09/592,695  
Filed: June 13, 2000  
For: Structured Peptide Scaffold for  
Displaying Tn5 Libraries on Phage

Group Art Unit: 1627

Examiner: T. Prasthofer

JAN 22 2001  
TECH CENTER 1600/2900

**CERTIFICATE OF MAILING**  
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on

October 29, 2001

Eileen Ly

RECEIVED

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT**  
**APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID**  
**SEQUENCE DISCLOSURES**

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

This is responsive to the Notice to Comply with Requirements For Patent Applications Containing Nucleotide Sequence And/or Amino Acid Sequence Disclosures dated September 27, 2001. Transmitted herewith are the following documents:

1. A substitute Sequence Listing, in paper copy and a computer readable diskette.
2. Certificate Re: Sequence Listing Response Under 37 CFR §1.821(f) and (g)
3. Copy of Notice to Comply with Requirements For Patent Applications Containing Nucleotide Sequence And/or Amino Acid Sequence Disclosures.

The substitute Sequence Listing is submitted to correct errors in the originally submitted "Sequence Listing". These errors, which mainly relate to "feature" information of various n's or Xaa's contained in subject sequences, have been identified in the Notice to Comply (a copy attached hereto), and are hereby corrected in compliance with the requirements of 37 CFR 1.821-1.825. SEQ ID NO:1 is hereby amended to replace Xaa at position 4 (which stands for 3-12 L-form amino acids as originally disclosed) with four specific amino acids Glu, Gly, Asn and Lys. The specific designation of Xaa at position 4 as GluGlyAsnLys is described in the specification at, for example, page 10, lines 16-21. Therefore, the replacement does not constitute new matter.

PL10B  
SAG/8  
1-24-02

In the event any additional fees are due in connection with the filing of these documents, the Commissioner is authorized to charge such fees to our Deposit Account No. 07-0630.

Respectfully submitted,

GENENTECH, INC.

By:

  
Steven X. Cui


Reg. No. 44,637

Telephone No. (650) 225-8674



09157

PATENT TRADEMARK OFFICE



*sx/ck*

UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

09/592,696 06/13/00 DOCHRAN

*PJ762R1*

HM2270920

EXAMINER

*PRASTHOFFER, T*

ART UNIT

PAPER NUMBER

*6-107*

DATE MAILED:

*Oct 12 2001*

**RECEIVED**

OCT 04 2001

GENENTECH, INC.  
LEGAL DEPT.

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

**CALENDARED/CK**  
*Comply*

27 OCT 01

**DUE DATE**



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/592,695	06/13/00	Andrea G. Cochran	P1762 RI

EXAMINER	
Thomas Prasthofer	
ART UNIT	PAPER NUMBER
1627	9

Please find below a communication from the EXAMINER in charge of this application

**Failure to Comply with Sequence Rules**

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures.

APPLICANT IS GIVEN 30 days FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.R.F. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Examiner, whose telephone number is (703) 308-4548. If the examiner cannot be reached, inquiries can be directed to Supervisory Patent Examiner, whose telephone number is (703) 308-2439. The fax number for the organization where this application or proceeding is assigned is (703) 308-2742.

Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist whose telephone number is (703) 308-1235.

Thomas Prasthofer


September 25, 2001

*J. Venkat*  
DR. JYOTHSNA VENKAT PH.D  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600

## NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):



1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).
2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
7. Other: \_\_\_\_\_

### Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support


Technical Assistance.....703-287-0200

To Purchase PatentIn Software .....703-306-2600

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY**

Korona  
BIOTECHNOLOGY  
SYSTEMS  
BRANCH

## RAW SEQUENCE LISTING ERROR REPORT



The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/592,695 #18  
Source: 1629  
Date Processed by STIC: 3/16/2001

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: [patin3help@uspto.gov](mailto:patin3help@uspto.gov) or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER VERSION 3.0 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND TRADEMARK OFFICE WEBSITE. SEE BELOW:


### Checker Version 3.0

The Checker Version 3.0 application is a state-of-the-art Windows based software program employing a logical and intuitive user-interface to check whether a sequence listing is in compliance with format and content rules. Checker Version 3.0 works for sequence listings generated for the original version of 37 CFR §§1.821 – 1.825 effective October 1, 1990 (old rules) and the revised version (new rules) effective July 1, 1998 as well as World Intellectual Property Organization (WIPO) Standard ST.25.

Checker Version 3.0 replaces the previous DOS-based version of Checker, and is Y2K-compliant. Checker allows public users to check sequence listings in Computer Readable form (CRF) before submitting them to the United States Patent and Trademark Office (USPTO).

Use of Checker prior to filing the sequence listing is expected to result in fewer errored sequence listings, thus saving time and money.

Checker Version 3.0 can be down loaded from the USPTO website at the following address:  
<http://www.uspto.gov/web/offices/pac/checker>



## Raw Sequence Listing Error Summary

<u>ERROR DETECTED</u>	<u>SUGGESTED CORRECTION</u>	<u>SERIAL NUMBER:</u> <u>09/592,695</u>
<b>ATTN: NEW RULES CASES: PLEASE DISREGARD ENGLISH "ALPHA" HEADERS, WHICH WERE INSERTED BY PTO SOFTWARE</b>		
1 <input type="checkbox"/> Wrapped Nucleic	The number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3, as this will prevent "wrapping".	
2 <input type="checkbox"/> Wrapped Aminos	The amino acid number/text at the end of each line "wrapped" down to the next line. This may occur if your file was retrieved in a word processor after creating it. Please adjust your right margin to .3, as this will prevent "wrapping".	
3 <input type="checkbox"/> Incorrect Line Length	The rules require that a line not exceed 72 characters in length. This includes spaces.	
4 <input type="checkbox"/> Misaligned Amino Acid Numbering	The numbering under each 5th amino acid is misaligned. This may be caused by the use of tabs between the numbering. It is recommended to delete any tabs and use spacing between the numbers.	
5 <input type="checkbox"/> Non-ASCII	This file was not saved in ASCII (DOS) text, as required by the Sequence Rules. Please ensure your subsequent submission is saved in ASCII text so that it can be processed.	
6 <input checked="" type="checkbox"/> Variable Length	Sequence(s) <u>1</u> contain n's or Xaa's which represented more than one residue. As per the rules, each n or Xaa can only represent a single residue. Please present the maximum number of each residue having variable length and indicate in the (ix) feature section that some may be missing.	
7 <input type="checkbox"/> PatentIn ver. 2.0 "bug"	A "bug" in PatentIn version 2.0 has caused the <220>-<223> section to be missing from amino acid sequence(s) <u>          </u> . Normally, PatentIn would automatically generate this section from the previously coded nucleic acid sequence. Please manually copy the relevant <220>-<223> section to the subsequent amino acid sequence. This applies primarily to the mandatory <220>-<223> sections for Artificial or Unknown sequences.	
8 <input type="checkbox"/> Skipped Sequences (OLD RULES)	Sequence(s) <u>      </u> missing. If intentional, please use the following format for each skipped sequence: (2) INFORMATION FOR SEQ ID NO:X: (i) SEQUENCE CHARACTERISTICS:(Do not insert any headings under "SEQUENCE CHARACTERISTICS") (xi) SEQUENCE DESCRIPTION:SEQ ID NO:X: This sequence is intentionally skipped  Please also adjust the "(iii) NUMBER OF SEQUENCES:" response to include the skipped sequence(s).	
9 <input type="checkbox"/> Skipped Sequences (NEW RULES)	Sequence(s) <u>      </u> missing. If intentional, please use the following format for each skipped sequence. <210> sequence id number <400> sequence id number 000	
10 <input type="checkbox"/> Use of n's or Xaa's (NEW RULES)	Use of n's and/or Xaa's have been detected in the Sequence Listing. Use of <220> to <223> is MANDATORY if n's or Xaa's are present. In <220> to <223> section, please explain location of n or Xaa, and which residue n or Xaa represents.	
11 <input checked="" type="checkbox"/> Use of <213>Organism (NEW RULES)	Sequence(s) <u>      </u> are missing this mandatory field or its response. <u>1</u>	
12 <input checked="" type="checkbox"/> Use of <220>Feature (NEW RULES)	Sequence(s) <u>      </u> are missing the <220>Feature and associated headings. Use of <220> to <223> is MANDATORY if <213>ORGANISM is "Artificial" or "Unknown" Please explain source of genetic material in <220> to <223> section. (See "Federal Register," 6/01/98, Vol. 63, No. 104, pp. 29631-32) (Sec. 1.823 of new Rules)	
13 <input type="checkbox"/> PatentIn ver. 2.0 "bug"	Please do not use "Copy to Disk" function of PatentIn version 2.0. This causes a corrupted file, resulting in missing mandatory numeric identifiers and responses (as indicated on raw sequence listing). Instead, please use "File Manager" or any other means to copy file to floppy disk.	



1627

B. Karoma  
RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/592,695

DATE: 03/16/2001  
TIME: 15:33:38

Input Set : A:\PTO.txt  
Output Set: N:\CRF3\03162001\I592695.raw

Does Not Comply  
Corrected Diskette Needed

3 <110> APPLICANT: Cochran, Andrea G.  
4 Skelton, Nicholas J.  
5 Starovasnik, Melissa A.  
7 <120> TITLE OF INVENTION: Structured Peptide Scaffold For Displaying Turn  
8 Libraries On Phage  
10 <130> FILE REFERENCE: P1762R1 US  
12 <140> CURRENT APPLICATION NUMBER: US 09/592,695  
13 <141> CURRENT FILING DATE: 2000-06-13  
15 <150> PRIOR APPLICATION NUMBER: US 60/139,017  
16 <151> PRIOR FILING DATE: 1999-06-14  
18 <160> NUMBER OF SEQ ID NOS: 25  
20 <210> SEQ ID NO: 1  
21 <211> LENGTH: 7  
22 <212> TYPE: PRT  
23 <213> ORGANISM: Artificial Sequence *See item 12 on Error Summary Sheet*  
25 <220> FEATURE:  
26 <223> OTHER INFORMATION: Xaa at positions 3 and 5 are selected from the group consisting of amino acids Trp, Tyr, Phe, Leu, Met, Ile and Val;  
27  
29 <220> FEATURE:  
W--> 30 <221> NAME/KEY: Artificial Sequence *These are not responses shown in WIPO Standard ST.25 Appendices*  
31 <222> LOCATION: Full  
32 <223> OTHER INFORMATION: Xaa at positions 2 and 6 are selected from the group consisting of amino acids Trp, Tyr, Phe, His, Ile, Val and Thr;  
33  
35 <220> FEATURE:  
W--> 36 <221> NAME/KEY: Artificial Sequence *not in WIPO Standard ST.25* *see 1.823 of new Sequence Rule*  
37 <222> LOCATION: Full  
38 <223> OTHER INFORMATION: Xaa at position 4 stands for 3-12 L-form amino acids. *see item 6 on Error Summary Sheet*  
40 <220> FEATURE:  
W--> 41 <221> NAME/KEY: unsure *These locations have been identified above*  
42 <222> LOCATION: 2-6  
43 <223> OTHER INFORMATION: unknown amino acid  
45 <400> SEQUENCE: 1  
W--> 46 Cys Xaa Xaa Xaa Xaa Xaa Cys  
47 1 5  
49 <210> SEQ ID NO: 2  
50 <211> LENGTH: 10  
51 <212> TYPE: PRT  
52 <213> ORGANISM: Artificial Sequence  
54 <220> FEATURE:  
55 <223> OTHER INFORMATION: turn peptide  
57 <400> SEQUENCE: 2  
58 Cys Thr Trp Glu Gly Asn Lys Leu Thr Cys  
59 1 5 10  
61 <210> SEQ ID NO: 3  
62 <211> LENGTH: 12  
63 <212> TYPE: PRT  
64 <213> ORGANISM: Artificial Sequence

RECEIVED

MAR 23 2001

TECH CENTER 1600/2900

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/592,695

DATE: 03/16/2001  
TIME: 15:33:38

Input Set : A:\PTO.txt  
Output Set: N:\CRF3\03162001\I592695.raw

66 <220> FEATURE:  
67 <223> OTHER INFORMATION: turn peptide  
69 <400> SEQUENCE: 3  
70 Ser Cys Thr Trp Glu Gly Asn Lys Leu Thr Cys Lys  
71 1 5 10  
73 <210> SEQ ID NO: 4  
74 <211> LENGTH: 10  
75 <212> TYPE: PRT  
76 <213> ORGANISM: Artificial Sequence  
78 <220> FEATURE:  
79 <223> OTHER INFORMATION: turn peptide  
81 <400> SEQUENCE: 4  
82 Cys Gly Asn Gln Gly Ser Phe Leu Thr Cys  
83 1 5 10  
85 <210> SEQ ID NO: 5  
86 <211> LENGTH: 10  
87 <212> TYPE: PRT  
88 <213> ORGANISM: Artificial Sequence  
90 <220> FEATURE:  
91 <223> OTHER INFORMATION: turn peptide  
93 <400> SEQUENCE: 5  
94 Cys Thr Trp Gln Gly Ser Phe Leu Thr Cys  
95 1 5 10  
97 <210> SEQ ID NO: 6  
98 <211> LENGTH: 12  
99 <212> TYPE: PRT  
100 <213> ORGANISM: Artificial Sequence  
102 <220> FEATURE:  
103 <223> OTHER INFORMATION: turn peptide  
105 <400> SEQUENCE: 6  
106 Ser Cys Gly Asn Gln Gly Ser Phe Leu Thr Cys Lys  
107 1 5 10  
109 <210> SEQ ID NO: 7  
110 <211> LENGTH: 12  
111 <212> TYPE: PRT  
112 <213> ORGANISM: Artificial Sequence  
114 <220> FEATURE:  
115 <223> OTHER INFORMATION: turn peptide  
117 <400> SEQUENCE: 7  
118 Ser Cys Thr Asn Gln Gly Ser Phe Leu Thr Cys Lys  
119 1 5 10  
121 <210> SEQ ID NO: 8  
122 <211> LENGTH: 12  
123 <212> TYPE: PRT  
124 <213> ORGANISM: Artificial Sequence  
126 <220> FEATURE:  
127 <223> OTHER INFORMATION: turn peptide  
129 <400> SEQUENCE: 8  
130 Ser Cys Gly Trp Gln Gly Ser Phe Leu Thr Cys Lys

## RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/592,695

DATE: 03/16/2001

TIME: 15:33:38

Input Set : A:\PTO.txt

Output Set: N:\CRF3\03162001\I592695.raw

131 1 5 10  
133 <210> SEQ ID NO: 9  
134 <211> LENGTH: 12  
135 <212> TYPE: PRT  
136 <213> ORGANISM: Artificial Sequence  
138 <220> FEATURE:  
139 <223> OTHER INFORMATION: turn peptide  
141 <400> SEQUENCE: 9  
142 Ser Cys Thr Trp Gln Gly Ser Phe Leu Thr Cys Lys  
143 1 5 10  
145 <210> SEQ ID NO: 10  
146 <211> LENGTH: 12  
147 <212> TYPE: PRT  
148 <213> ORGANISM: Artificial Sequence  
150 <220> FEATURE:  
151 <223> OTHER INFORMATION: turn peptide  
153 <400> SEQUENCE: 10  
154 Ser Cys Gly Asn Gln Gly Ser Phe Leu Thr Cys Lys  
155 1 5 10  
157 <210> SEQ ID NO: 11  
158 <211> LENGTH: 12  
159 <212> TYPE: PRT  
160 <213> ORGANISM: Artificial Sequence  
162 <220> FEATURE:  
163 <223> OTHER INFORMATION: turn peptide  
165 <400> SEQUENCE: 11  
166 Ser Cys Thr Trp Gln Gly Ser Phe Leu Thr Cys Lys  
167 1 5 10  
169 <210> SEQ ID NO: 12  
170 <211> LENGTH: 10  
171 <212> TYPE: PRT  
172 <213> ORGANISM: Artificial Sequence  
174 <220> FEATURE:  
175 <223> OTHER INFORMATION: turn peptide  
177 <400> SEQUENCE: 12  
178 Cys Thr Lys Val Trp Gln Leu Trp Thr Cys  
179 1 5 10  
181 <210> SEQ ID NO: 13  
182 <211> LENGTH: 12  
183 <212> TYPE: PRT  
184 <213> ORGANISM: Artificial Sequence  
186 <220> FEATURE:  
187 <223> OTHER INFORMATION: turn peptide  
189 <400> SEQUENCE: 13  
190 Ser Cys Thr Trp Val Trp Gln Leu Leu Thr Cys Lys  
191 1 5 10  
193 <210> SEQ ID NO: 14  
194 <211> LENGTH: 12  
195 <212> TYPE: PRT

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/592,695

DATE: 03/16/2001  
TIME: 15:33:38

Input Set : A:\PTO.txt  
Output Set: N:\CRF3\03162001\I592695.raw

196 <213> ORGANISM: Artificial Sequence  
198 <220> FEATURE:  
199 <223> OTHER INFORMATION: turn peptide  
201 <400> SEQUENCE: 14  
202 Ser Cys His Phe Gly Pro Leu Thr Trp Val Cys Lys  
203 1 5 10  
205 <210> SEQ ID NO: 15  
206 <211> LENGTH: 12  
207 <212> TYPE: PRT  
208 <213> ORGANISM: Artificial Sequence  
210 <220> FEATURE:  
211 <223> OTHER INFORMATION: turn peptide  
213 <400> SEQUENCE: 15  
214 Ser Cys Thr Trp Gly Pro Leu Thr Leu Thr Cys Lys  
215 1 5 10  
217 <210> SEQ ID NO: 16  
218 <211> LENGTH: 10  
219 <212> TYPE: PRT  
220 <213> ORGANISM: Artificial Sequence  
222 <220> FEATURE:  
223 <223> OTHER INFORMATION: turn peptide; Xaa is Trp, Tyr, Leu, Val, Thr or Asp.  
225 <220> FEATURE:  
226 <221> NAME/KEY: unsure ?  
227 <222> LOCATION: 3  
228 <223> OTHER INFORMATION: unknown amino acid  
230 <400> SEQUENCE: 16  
231 Cys Thr Xaa Glu Gly Asn Lys Leu Thr Cys  
232 1 5 10  
234 <210> SEQ ID NO: 17  
235 <211> LENGTH: 10  
236 <212> TYPE: PRT  
237 <213> ORGANISM: Artificial Sequence  
239 <220> FEATURE:  
240 <223> OTHER INFORMATION: turn peptide; Xaa is Trp, Tyr, Leu, Val, Thr or Asp.  
242 <220> FEATURE:  
243 <221> NAME/KEY: unsure  
244 <222> LOCATION: 3  
245 <223> OTHER INFORMATION: unknown amino acid  
247 <400> SEQUENCE: 17  
W--> 248 Cys Thr Xaa Glu Asn Gly Lys Leu Thr Cys  
249 1 5 10  
251 <210> SEQ ID NO: 18  
252 <211> LENGTH: 10  
253 <212> TYPE: PRT  
254 <213> ORGANISM: Artificial Sequence  
256 <220> FEATURE:  
257 <223> OTHER INFORMATION: turn peptide; Xaa is Trp, Tyr, Leu, Val, Thr or Asp.  
259 <220> FEATURE:  
260 <221> NAME/KEY: unsure

Xaa has been identified  
as one of the above.

same discrepancy as above

Name

RAW SEQUENCE LISTING  
PATENT APPLICATION: US/09/592,695

DATE: 03/16/2001  
TIME: 15:33:38

Input Set : A:\PTO.txt  
Output Set: N:\CRF3\03162001\I592695.raw

```

261 <222> LOCATION: 3
262 <223> OTHER INFORMATION: unknown amino acid
264 <400> SEQUENCE: 18
W--> 265 Cys Thr Xaa Glu Pro Asn Lys Leu Thr Cys
266 1 5 10
268 <210> SEQ ID NO: 19
269 <211> LENGTH: 10
270 <212> TYPE: PRT
271 <213> ORGANISM: Artificial Sequence
273 <220> FEATURE:
274 <223> OTHER INFORMATION: turn peptide; Xaa is Trp, Tyr, Leu, Val, Thr or Asp.
276 <220> FEATURE:
277 <221> NAME/KEY: unsure
278 <222> LOCATION: 3
279 <223> OTHER INFORMATION: unknown amino acid same
281 <400> SEQUENCE: 19
W--> 282 Cys Thr Xaa Glu Pro Gly Lys Leu Thr Cys
283 1 5 10
285 <210> SEQ ID NO: 20
286 <211> LENGTH: 10
287 <212> TYPE: PRT
288 <213> ORGANISM: Artificial Sequence
290 <220> FEATURE:
291 <223> OTHER INFORMATION: Xaa is Trp, Tyr, Phe, Leu, Met, Ile, Val or Ala
293 <220> FEATURE:
294 <221> NAME/KEY: unsure
295 <222> LOCATION: 3
296 <223> OTHER INFORMATION: unknown amino acid same
298 <400> SEQUENCE: 20
W--> 299 Cys Thr Xaa Glu Gly Asn Lys Leu Thr Cys
300 1 5 10
302 <210> SEQ ID NO: 21
303 <211> LENGTH: 10
304 <212> TYPE: PRT
305 <213> ORGANISM: Artificial Sequence
307 <220> FEATURE:
308 <223> OTHER INFORMATION: Xaa is Trp, Tyr, Phe, Leu, Met, Ile, Val or Ala
310 <220> FEATURE:
311 <221> NAME/KEY: unsure
312 <222> LOCATION: 8
313 <223> OTHER INFORMATION: unknown amino acid same
315 <400> SEQUENCE: 21
W--> 316 Cys Thr Leu Glu Gly Asn Lys Xaa Thr Cys
317 1 5 10
319 <210> SEQ ID NO: 22
320 <211> LENGTH: 10
321 <212> TYPE: PRT
322 <213> ORGANISM: Artificial Sequence
324 <220> FEATURE:

```

Please correct these errors  
in subsequent sequences too.

FYI

Pleas Note:

Use of n and/or Xaa have been detected in the Sequence Listing. Please review the Sequence Listing to ensure that a corresponding explanation is presented in the <220> to <223> fields of each sequence which presents at least one non-Xaa.

## VERIFICATION SUMMARY

PATENT APPLICATION: US/09/592,695

DATE: 03/16/2001

TIME: 15:33:39

Input Set : A:\PTO.txt

Output Set: N:\CRF3\03162001\I592695.raw

L:30 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:1  
L:36 M:257 W: Feature value mis-spelled or invalid, <221> Name/Key for SEQ ID#:1  
L:46 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:1  
L:231 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:16  
L:248 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:17  
L:265 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:18  
L:282 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:19  
L:299 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:20  
L:316 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:21  
L:333 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:22  
L:350 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:23  
L:382 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25  
L:384 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:25



Patent Docket P 742R1

TECH CENTER 1600/2900  
JAN 22 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  Andrea G. Cochran et al.  Serial No.: 09/592,695  Filed: June 13, 2000  For: Structured Peptide Scaffold for Displaying Turn Libraries on Phage	Group Art Unit: 1627  Examiner: T. Prasthofer
<p><b>CERTIFICATE OF MAILING</b> I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231 on</p> <p>October 29, 2001</p> <p>Eileen Ly</p>	

**CERTIFICATE RE: SEQUENCE LISTING**

**RESPONSE UNDER 37 CFR § 1.821(f) and (g)**

Assistant Commissioner of Patents  
Washington, D.C. 20231

Sir:

I hereby state that the Sequence Listing submitted herewith is submitted in paper copy and a computer-readable diskette, and that the information recorded in computer readable form is identical to the written sequence listing. I further state that this submission includes no new matter.

Respectfully submitted,

GENENTECH, INC.

By: Steven X. Cui  
Steven X. Cui  
Reg. No. 44,637  
Telephone No. (650) 225-8674

Date: October 29, 2001



09157

PATENT TRADEMARK OFFICE

#99108

RECEIVED